在线QQ: 五斗堂面馆
    专题栏目
    专业术语
    ISPN词汇 小儿血液系统疾病
    ISPN词汇 小儿肌肉骨骼系统疾病
    出国资讯
    美国宣布重大移民改革议案取消公民...
    2017美国护士薪资调查报告新鲜出炉
    医护前沿
    《ISPN学习》总第506期
    《ISPN学习》总第505期
     
    当前位置:首页 > 出国资讯
    《临床肿瘤科护理杂志》总第20.5期增
    日期:2016-11-15 08:51:43    来源:ISPN周老师
     
    《临床肿瘤科护理杂志》2016年10月总第20卷第5期增刊
    Clinical Journal of Oncology Nursing
    October 2016 Vol. 20, No. 5 Supplement
     
    Article
    Glioblastoma: Overview of Disease and Treatment
    胶质母细胞瘤:疾病与治疗概述
    Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Significant advances in the understanding of the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies for recurrent and newly diagnosed disease. Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival.
    Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy
    肿瘤电场疗法治疗胶质母细胞瘤的效应与安全性
    Glioblastoma (GBM) is a highly aggressive astrocytoma with a dismal prognosis. Since 1976, only three chemotherapeutic agents have been approved for the treatment of GBM. Tumor-treating fields (TTFields) therapy, delivered via a noninvasive device, is a new therapy approved for use in patients with recurrent GBM and in combination with temozolomide for the treatment of newly diagnosed GBM.
    Optune®: Practical Nursing Applications
    Optune®:在护理中的应用
    After receiving U.S. Food and Drug Administration approval for the treatment of newly diagnosed glioblastoma (GBM) in 2015, following initial approval for treatment of recurrent GBM in 2011, Optune®, a device that uses tumor-treating fields (TTFields) therapy, continues to gain acceptance in the practice environment.
    Rationale and Background on Tumor-Treating Fields for Glioblastoma
    肿瘤电场疗法治疗胶质母细胞瘤的原理和背景
    More than 150 years after the first description of glioma cells, patients with glioblastoma (GBM) continue to have a poor prognosis despite standard-of-care therapy. With the introduction of tumor-treating fields (TTFields) therapy for the treatment of recurrent GBM in 2011 and for newly diagnosed GBM in 2015, the opportunity to increase progression-free survival and overall survival while improving quality of life provides a welcome option. 
     




    上一篇:《临床肿瘤科护理杂志》总第20.5期
    下一篇:《临床护理专家》总第30.6期